Related Experiment Videos
Vaccine strategies to prevent rheumatic fever
1Molecular Immunology Laboratory, The Co-operative Centre for Vaccine Technology, Queensland Institute of Medical Research. michaelG@qimr.edu.au
Abstract:
Group A streptococci (GAS) are responsible for numerous human illnesses, ranging from pharyngitis to severe invasive infections, such as necrotizing fascitis and toxic shock syndrome to the postinfectious sequelae, acute rheumatic fever (ARF), and glomerulonephritis. To date, to develop a vaccine, studies have focused on the M protein. However, designing a vaccine to prevent GAS infection based on this molecule has been hampered by the vast number of M protein serotypes and the possibility that it may induce potentially harmful autoimmune reactions. In this article, the authors discuss recent approaches to overcoming the problems of an M protein-based vaccine. In addition, recent studies identifying the protective properties of other streptococcal antigens and their potential as vaccine candidates are discussed.
Insights
Developing a Group A Streptococcus (GAS) vaccine faces challenges due to M protein diversity and autoimmune risks. This review explores alternative GAS antigens as promising vaccine candidates to overcome these limitations.
Area of Science:
- Microbiology
- Immunology
- Vaccinology
Background:
- Group A Streptococcus (GAS) causes diverse human illnesses, from pharyngitis to severe invasive diseases and postinfectious sequelae like acute rheumatic fever.
- Current vaccine development efforts primarily target the M protein, a major GAS virulence factor.
- Limitations of M protein-based vaccines include extensive serotype variability and potential for autoimmune adverse reactions.
Purpose of the Study:
- To review recent strategies for developing an effective Group A Streptococcus (GAS) vaccine.
- To discuss the challenges associated with M protein-based vaccine approaches.
- To explore alternative GAS antigens with protective properties as potential vaccine candidates.
Main Methods:
- Literature review of recent studies on GAS vaccine development.
- Analysis of M protein-based vaccine strategies and their limitations.
- Identification and evaluation of other GAS antigens investigated for vaccine potential.
Main Results:
- M protein-based vaccine development is hindered by numerous serotypes and risks of autoimmune responses.
- Alternative streptococcal antigens are being investigated for their immunogenic and protective capabilities.
- Emerging research highlights other GAS components as viable vaccine targets.
Conclusions:
- Overcoming M protein-related vaccine challenges is crucial for effective GAS prevention.
- Exploring alternative antigens offers a promising path towards a broadly protective GAS vaccine.
- Further research into novel GAS vaccine candidates is warranted to address the global burden of streptococcal infections.